001     169082
005     20250127124930.0
024 7 _ |a 10.5061/DRYAD.G3B5272
|2 doi
024 7 _ |a 10.5061/dryad.g3b5272
|2 doi
037 _ _ |a DZNE-2022-01789
041 _ _ |a English
100 1 _ |a Arnoux, Isabelle
|b 0
245 _ _ |a Dataset: Data from: Metformin reverses early cortical network dysfunction and behavior changes in Huntington’s disease
260 _ _ |c 2018
|b Dryad
336 7 _ |a MISC
|2 BibTeX
336 7 _ |a Dataset
|b dataset
|m dataset
|0 PUB:(DE-HGF)32
|s 1737978554_6605
|2 PUB:(DE-HGF)
336 7 _ |a Chart or Table
|0 26
|2 EndNote
336 7 _ |a Dataset
|2 DataCite
336 7 _ |a DATA_SET
|2 ORCID
336 7 _ |a ResearchData
|2 DINI
520 _ _ |a Catching primal functional changes in early, “very far from disease onset” (VFDO) stages of Huntington’s disease is likely to be the key to a successful therapy. Focusing on VFDO stages, we assessed neuronal microcircuits in premanifest Hdh150 knock-in mice. Employing in vivo two-photon Ca2+ imaging, we revealed an early pattern of circuit dysregulation in the visual cortex- one of the first regions affected in premanifest Huntington’s disease - characterized by an increase in activity, an enhanced synchronicity and hyperactive neurons. These findings are accompanied by aberrations in animal behavior. We furthermore show that the anti-diabetic drug metformin diminishes aberrant Huntingtin protein load and fully restores both, early network activity patterns and behavioral aberrations. This network-centered approach reveals a critical window of vulnerability far before clinical manifestation and establishes metformin as a promising candidate for a chronic therapy starting early in premanifest Huntington’s disease pathogenesis long before the onset of clinical symptoms.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to DataCite
650 _ 7 |a cortical microcircuits
|2 Other
650 _ 7 |a Huntington disease
|2 Other
650 _ 7 |a in vivo calcium imaging
|2 Other
650 _ 7 |a metformin
|2 Other
650 _ 7 |a neuronal hyperactivity
|2 Other
700 1 _ |a Willam, Michael
|b 1
700 1 _ |a Griesche, Nadine
|0 P:(DE-2719)2690834
|b 2
|u dzne
700 1 _ |a Krummeich, Jennifer
|0 P:(DE-2719)2812064
|b 3
|u dzne
700 1 _ |a Watari, Hirofumi
|b 4
700 1 _ |a Offermann, Nina
|0 P:(DE-2719)2811777
|b 5
|u dzne
700 1 _ |a Weber, Stephanie
|0 P:(DE-2719)2662310
|b 6
|u dzne
700 1 _ |a Narayan Dey, Partha
|b 7
700 1 _ |a Chen, Chen
|b 8
700 1 _ |a Monteiro, Olivia
|b 9
700 1 _ |a Buettner, Sven
|0 P:(DE-2719)2809898
|b 10
|u dzne
700 1 _ |a Meyer, Katharina
|0 P:(DE-2719)2401927
|b 11
|u dzne
700 1 _ |a Bano, Daniele
|0 P:(DE-2719)2158358
|b 12
|u dzne
700 1 _ |a Radyushkin, Konstantin
|b 13
700 1 _ |a Langston, Rosamund
|b 14
700 1 _ |a Lambert, Jeremy J.
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Wanker, Erich
|b 16
700 1 _ |a Methner, Axel
|b 17
700 1 _ |a Krauss, Sybille
|0 P:(DE-2719)2421562
|b 18
|u dzne
700 1 _ |a Schweiger, Susann
|b 19
700 1 _ |a Stroh, Albrecht
|b 20
773 _ _ |a 10.5061/dryad.g3b5272
909 C O |p VDB
|o oai:pub.dzne.de:169082
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2690834
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2812064
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811777
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2662310
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2809898
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2401927
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2158358
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2421562
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2018
920 1 _ |0 I:(DE-2719)1011006
|k AG Krauß
|l Regulatory RNA-protein interaction in neurodegenerative diseases
|x 0
920 1 _ |0 I:(DE-2719)1013003
|k AG Bano
|l Aging and Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1013033
|k AG Capasso
|l Immune Regulation
|x 2
920 1 _ |0 I:(DE-2719)1040300
|k Biorepository
|l Biorepository
|x 3
980 _ _ |a dataset
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011006
980 _ _ |a I:(DE-2719)1013003
980 _ _ |a I:(DE-2719)1013033
980 _ _ |a I:(DE-2719)1040300
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21